Roche‘s (OTC:RHHBY) Genentech said today that the FDA approved its ACTPen single-dose prefilled autoinjector for Actemra as a new formulation for adults with moderate to severe active rheumatoid arthritis and for adults with giant cell arteritis.
The U.S. regulatory agency also approved the device for administration by caregivers to patients as young as two years old with active polyarticular juvenile idiopathic arthritis or active systemic juvenile idiopathic arthritis.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves Genentech’s prefilled autoinjector for Actemra appeared first on MassDevice.
from MassDevice https://ift.tt/2DKvwxw
Cap comentari:
Publica un comentari a l'entrada